---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020833"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:30:01.325343+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q1 net loss $19.2M; cash $150.8M; ODD for PYX-201 in pancreatic cancer

## Summary
- Net loss of $19.2M ($0.54 per share) vs $31.4M ($0.97) in Q1 2022; R&D expenses $11.9M, G&A $9.1M.
- Cash, equivalents, restricted cash and short-term investments $150.8M, no debt; runway into 1H 2025.
- FDA granted Orphan Drug Designation for PYX-201 in pancreatic cancer; Phase 1 trial dosing underway.
- Phase 1 trial of PYX-106 dosing expected to begin Q2 2023; preliminary data from both trials late 2023 to early 2024.
- One-time $8M payment to Pfizer in Q1 for FACT platform license expansion.

## SEC filing metadata
- accession: 0000950170-23-020833
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/0000950170-23-020833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/pyxs-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020833
- JSON: https://secwatch.observer/filing/0000950170-23-020833.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020833.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023, EPS $0.54 per common share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023
  - EPS: $0.54 per common share
  - Result: reported results
  source text: Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/0000950170-23-020833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.